Other names: EC 3. 
Transcription
SHIP2 promoter is regulated by Sp1 transcription factors (Ishida et al., 2005) . Mechanisms of transcriptional regulations are unknown and perhaps not present. SHIP2 mRNA is expressed ubiquitously at high levels (Pesesse et al., 1997; Habib et al., 1998) and the protein levels are regulated post-transcriptionally by microRNA-205 (inhibitory) or microRNA-184 (which is a suppressor of mir-205) (Yu et al., 2008) .
Protein
Description SHIP2 protein (1258 amino acids long) contains an inositol polyphosphate phosphatase domain (IPPc; . In addition, SHIP2 has an amino-terminal SH2-domain (aa 21-117) and a carboxyl-terminal proline-rich region (Pro-rich; aa 935-1105) . Also, SHIP2 contains a NPXY motif (aa 983-986) and a SAM (sterile alpha-motif) domain (aa 1201-1258).
These structural elements provide sites for proteinprotein interactions which seem to play a major role in SHIP2 function. Several cellular proteins associate with SHIP2 via phosphotyrosine-dependent (SH2 or NPXY mediated) or proline-rich region (SH3 mediated) interactions (for a comprehensive list of interacting proteins and citations please see Prasad, 2009a) .
Expression
Ubiquitously expressed with higher levels of mRNA in skeletal muscle, liver, adipose tissue, placenta and brain (Pesesse et al., 1997; Habib et al., 1998; Muraille et al., 2001) . Also expressed in B-cells, T-cells, platelets, mast cells and macrophages (Muraille et al., 1999; Dyson et al., 2003; Giuriato et al., 2003; Ai et al., 2006; Leung and Bolland, 2007) . Protein levels are very low in normal tissues and cells. Higher levels of protein expression are noted in many types of cancer cells (Wisniewski et al., 1999; Prasad et al., 2001; Prasad and Decker 2005) and in human breast cancer tissues . SHIP2 protein levels in skeletal muscle and fat are higher in obese db/db mice as compared to normal heterozygous (db/+) mice and SHIP2 protein levels are moderately increased in response to a high-fat diet in normal mice (Hori et al., 2002) . SHIP2 genetic sequence in diabetic rats and humans contain mutations that may lead to increased levels of SHIP2 (Marion et al., 2002) .
Localisation
SHIP2 is diffusely cytoplasmic but membrane enrichment of SHIP2 occurs during cell attachment (Prasad et al., 2001) , membrane ruffling (Dyson et al., 2001) or in response to m-CSF in macrophages . Mutation in the SH2-domain (R47G) causes punctate distribution pattern in the cytoplasm of HeLa cells (Prasad et al., 2001 ). SHIP2 has also been reported to localize to the nuclear speckles in vascular smooth muscle cells (Deleris et al., 2003) .
Function
Overview. Phosphoinositide (PI) lipids are important second messengers in the intracellular signaling pathways. PI lipids interact with the pleckstrin homology domain (PH-domain) containing cellular enzymes causing their membrane recruitment and/or allosteric activation. Phosphoinositide 3-kinase (PI3-kinase) is central to the signal-induced generation of new phosphoinositides and its activation is a key intermediate step in the signaling initiated by various external signals including many hormones (insulin and leptin), growth factors (EGF, IGF-1 and PDGF) as well as integrin ligation. SHIP2 dephosphorylates the 5-position of phosphatidylinositol-3,4,5-trisphosphate (PIP3) generated by the PI3-kinase, producing a new second messenger PI-3,4-bisphosphate (PI-3,4-P2). As PI3-kinase pathway aberrations play a major role in the development of cancer, diabetes and inflammation, SHIP2 function is expected to be critically important for the molecular pathogenesis of these diseases. SHIP2 also dephosphorylates PI-3,4-bisphosphate (Taylor et al., 2000) . In vitro, a soluble inositol molecule, inositol-1,3,4,5-tetrakisphosphate (IP4) also serves as a high affinity substrate for SHIP2 (Pesesse et al., 1998; Chi et al., 2004; Batty et al., 2007) . Negative Regulator of insulin signaling. In cell culture overexpression studies, SHIP2 acts a mild suppressor of insulin signaling Wada et al., 2001) . RNA interference studies, however, contradict these observations Huard et al., 2007) . SHIP2 null-mice are viable but resistant to high-fat-diet-induced obesity (Sleeman et al., 2005) . Insulin signaling was enhanced only modestly in these mice. However, liver-specific suppression of SHIP2 function in mice improves insulin function (Fukui et al., 2005; . Mechanisms by which SHIP2 achieves the energy homeostasis therefore remain unclear at present. Negative Regulator of IGF-1 signaling. Exogenous SHIP2 in C2C12 skeletal muscle cells is shown to suppress IGF-1 signaling and to interfere with IGF-1-induced muscle hypertrophy (Rommel et al., 2001) . Similarly SHIP2 blocks compensatory hypertrophy upon its exogenous expression in rat skeletal muscle myocytes . Positive Regulator of cytoskeleton remodeling, cell adhesion, lamellipodia formation/cell spreading. Transient exogenous expression of the wild type-SHIP2 increases cellular adhesion in SH2-domain dependent manner in HeLa cells (Prasad et al., 2001 ). Furthermore, catalytic activity of SHIP2 is important for efficient lamellipodia formation and cell spreading (Prasad et al., 2001) . Interaction with c-Met is important for this function of SHIP2 in MDCK cells (Koch et al., 2005) . Also, C-terminus proline-rich region of SHIP2 is shown to be important for membrane ruffling process through its interaction with Filamin (Dyson et al., 2003) . Src kinase-induced tyrosine phosphorylation of SHIP2 and consequent SHIP2-Shc association are important for HeLa cell spreading on type I collagen (Prasad et al., 2002) . In MDA-231 breast cancer cells, SHIP2 promotes cell migration and this effect is associated to sustained EGFR-Akt signaling and increased expression of chemokine receptor CXCR4 (Prasad, 2009b) . Negative Regulator of endocytosis (EGFR, Transferrin receptor, EphA2). Suppression of endogenous SHIP2 in cancer cells (HeLa cervical cancer cells and MDA-231 breast cancer cells) decreases ligand-induced endocytosis of the EGFR and EphA2 (Prasad and Decker, 2005; Zhuang et al., 2007) . SHIP2 function in the endocytosis of EGFR is characterized by a direct and constitutive association between SHIP2 and c-Cbl ubiquitin ligase and changes in EGFR-Cbl association. Whereas SHIP2 directly interacts with EphA2 via SAM-domain and this interaction may be important for EphA2 endocytosis (Zhuang et al., 2007) . SHIP2 associates with intersectin 1, a major regulator of EGFR endocytosis, and recruits it to the plasma membrane in response to EGF treatment (Xie et al., 2008) .
Regulator of Cell Cycle progression and apoptosis.
Early studies indicated a positive association between SHIP2 expression and cell proliferation where EGF increases the SHIP2 mRNA expression in thyrocytes (Pesesse et al., 1997) . In addition, SHIP2 protein expression correlates with the EGFR expression in proliferating neurospheres (Muraille et al., 2001 ). Exogenous overexpression (using adenovirus vectors) of wild-type SHIP2 inhibits cell cycle progression in U87-MG glioblastoma cells (Taylor et al., 2000) and K562 leukemia cells (Giuriato et al., 2002) and of a dominant-negative SHIP2 (phosphatase-defective) increases proliferation of pancreatic beta-cells . Whereas retroviral-mediated expression of SHIP2 does not inhibit cell cycle progression of Myeloma cells (Choi et al., 2002) . Furthermore, RNAi-mediated suppression of endogenous SHIP2 in MDA-231 cells inhibits cell proliferation with G1 accumulation and decreased Sphase and delays in vivo tumorigenesis . Retroviral-mediated expression of a catalytically inactive SHIP2 inhibits PDGF-induced proliferation of 3T3-L1 preadipocytes (Artemenko et al., 2009 ). Thus, this aspect of SHIP2 function appears to be influenced greatly by the experimental approach and/or the cell types employed. Negative regulator of immune cell function. SHIP2 inhibits Fcgamma Receptor IIa signaling including Akt activation and NF-kb-dependent gene trasncription (Pengal et al., 2003) , downregulates Fcgamma Receptor-mediated phagocytosis (Ai et al., 2006 ) and decreases mast cell degranulation (Leung and Bolland, 2007; Saini et al., 2009 ).
Homology
SHIP2 is structurally related to SHIP1, another phosphoinositol 5-phosphatase expressed exclusively in hematopoietic tissues. SHIP1 is an important negative regulator of immune receptor and cytokine signaling. SHIP1 and SHIP2 show 64% identity in their inositol phosphatase domains and 54% identity in their SH2-domains.
The C-terminus proline-rich region carries the least similarity (also the SAM-domain is present only in SHIP2 and not in SHIP1) and appears to be the key for functional divergence between these two enzymes. In addition to the human gene, SHIP2 gene has been cloned from mouse, rat, cattle, dog, monkey, chimpanzee and zebra fish genomes.
Mutations

Germinal
There is R1142C mutation within the Proline-rich region of SHIP2 in Goto-Kakizaki (GK rats; a model for type 2 diabetes) and spontaneously hypertensive (SH-) rats. This mutation slightly impairs insulin signaling in cell culture (Marion et al., 2002) .
Somatic
In humans, a deletion in the SHIP2 3' untranslated region (UTR) has been identified in type 2 diabetic patients. In cell culture, this deletion enhances SHIP2 promoter activity in reporter assays and SHIP2 overexpression. This deletion is reported to be significantly associated with the presence of type 2 diabetes (Marion et al., 2002) .
Implicated in
Chronic myelogenous leukemia (CML)
Note SHIP2 is expressed at high levels in Bcr-Abl transformed K562 CML cells where it is highly tyrosine phosphorylated and constitutively associated with the adapter protein Shc in K562 leukemia cells (Wisniewski et al., 1999) . Adenoviral-mediated exogenous overexpression of SHIP2 in K562 cells inhibits cell cycle progression (see 'Function -Cell cycle regulation' above).
Breast cancer
Note SHIP2 is overexpressed in many breast cancer cells when compared to non-transformed mammary epithelial cells . Stable SHIP2 RNA interference in MDA-231 and MDA-468 breast cancer cells decreases cell proliferation Prasad, 2009b) . SHIP2 suppression also causes delayed tumorigenesis in nude mouse mammary fatpad xenograft studies . SHIP2 overexpression is reported in clinical specimens of human breast cancers [n=65 ; and n=285 ]. In invasive breast cancers (n=145), SHIP2 expression is positively correlated with reduced disease-free survival and estrogen receptornegative (ER-) and EGF receptor-positive (EGFR+) status .
Hepatocellular carcinoma
Note SHIP2 expression in the cancer cells is decreased as compared to the adjacent normal cells of the same cancer specimens (n = 20) (Sumie et al., 2007) . Any possible association between the SHIP2 levels and glucose intolerance or the aggressiveness of the disease remains to be examined.
Type 2 diabetes
Note Single nucleotide polymorphisms (SNPs) in the SHIP2 gene promoter and the 5' untranlated region correlates with the impaired fasting glycemia in Japanese population (Ishida et al., 2006) . The haplotypes found more frequently in glucose intolerant people increase transcription from SHIP2 promoter in reporter gene assays. Evidence from transgenic animal studies in mouse showed that SHIP2 function in liver is important for insulin-dependent glucose homeostasis (Fukui et al., 2005; Buettner et al., 2007; Kagawa et al., 2008) . Metabolic syndrome. Single nucleotide polymorphisms (SNPs) and haplotypes of SHIP2 are significantly correlated with symptoms of the metabolic syndrome including hypertension in British and French people from type 2 Diabetes families (Kaisaki et al., 2004) . This association was not found with essential hypertension (not linked to metabolic syndrome) (Marcano et al., 2007) . Obesity. Evidence from gene knockout studies in mouse showed that SHIP2 deletion caused resistance to high-fat diet induced obesity (Sleeman et al., 2005) although insulin signaling was only mildly enhanced. These studies raised the possibility that global inhibition of SHIP2 will be tolerated (not lethal) without significant side-effects. 
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